ECT
31.1.2020 10:32:09 CET | Business Wire | Press release
ECT (European Computer Telecoms AG), Europe’s leading communications software company for the realization of value-added services, announces that the company again achieved record growth in 2019. The company experienced an annual order intake of over 23 million EUR. Although the company’s audited, consolidated annual report has yet be completed, it is already clear that in 2019 ECT exceeded the 20% top-line growth achieved in the previous year, while the bottom line grew by over 30%. In addition, due to the high order backlog at the close of 2019 and maintenance contracts for 2020, ECT already has more than 12 million EUR on its books for this year and anticipates continued record growth.
This landmark development is in line with the Board’s long-term goal of maintaining at least 20% year-to-year revenue growth. As Marshall E. Kavesh, the CEO and cofounder of ECT, explains, “after more than 20 years as a profitable, but midsized market player, we last year took on the ambitious goal of growing ECT from a 20 million Euro to a 100 million Euro company by no later than 2025. With the excellent results of the last two years we have made important steps in this direction. Our continued growth, profitability, customer relationships and innovations are the foundation for the long-term prosperity and independence of our company. This is a commitment we make to all the colleagues in our fantastic ECT team and especially to our much appreciated customers.”
Key highlights for 2019 include:
Expanded Depth and Breadth of Customer Relationships
- The vast majority of the orders were received from first-tier carriers which have been ECT customers for 10 years and longer, attesting to the deep satisfaction of the company’s customer base.
- In addition, the company, whose roots are in Europe, continued to expand its footprint in the Americas with new customer acquisitions and conducted direct sales worldwide.
- With one of Finland’s leading telecommunications operators, DNA, the company closed a three-year contract worth many millions of euros for the provision of, amongst other things, licenses for ECT’s application for Virtual PBX / Unified Communications, a license for the Service Creation Environment of the company’s Telephony Application Server (TAS) as well as the utilization of a Dedicated Agile Programming Squad .
- In indirect sales via its partner Nokia Software, the company took part in tenders worldwide, e.g. closing yet another major multimillion deal.
Major Investments in Cutting-Edge Telecoms Technology
- The company founded a new R&D unit for NFVi architecture, implemented integration with Nokia’s CloudBand Application Manager (CBAM) and plans to continue certification with other major VNF Managers in 2020. Few competitors are capable of offering this important, cost-reducing technology.
- All new solutions are implemented based on ECT’s VNFs with the option of full integration with a third-party VNF Manager, providing Automated Lifecycle Management.
- ECT implemented agile methodology throughout the company starting in January 2019 and also launched a program allowing CSPs to take under contract an ECT Dedicated Agile Programming Squad, enabling them to respond in extremely short cycles to the customizations and enhancements demanded by their major corporate and municipal customers.
- Within the framework of ECT’s Joint Agile Product Development, the company’s Innovation Department successfully launched its cutting-edge application for unified communications and collaboration, ECT Workspace, with selected CSPs.
Rapid Organization Growth
- Although many other telecoms vendors are in retrenchment, ECT is accelerating the growth of its team: In 2019, the number of employees increased by ca. 25% compared to 2018 and is expected to grow by at least another 25% by the end of this year, the majority of the new positions being in R&D.
About ECT (European Computer Telecoms AG):
For more information about ECT, please visit our website: www.ect-telecoms.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom